128 related articles for article (PubMed ID: 37665180)
1. The utility of H2 receptor antagonists in preventing infusion-related reactions to paclitaxel chemotherapy.
Tsang C; Robinson J; Wheatley-Price PF; Brule SY; Moore SM
Cancer; 2023 Dec; 129(23):3815-3819. PubMed ID: 37665180
[TBL] [Abstract][Full Text] [Related]
2. Histamine-2 (H
Foreman E; Polwart C; Walker A; Chambers P
Br J Clin Pharmacol; 2022 Sep; 88(9):4191-4198. PubMed ID: 35470452
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.
Slichenmyer WJ; Donehower RC; Chen TL; Bowling MK; McGuire WP; Rowinsky EK
Cancer Chemother Pharmacol; 1995; 36(3):227-32. PubMed ID: 7781143
[TBL] [Abstract][Full Text] [Related]
4. Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.
Parinyanitikul N; Tanpipattanakul W; Poovorawan N; Rattananupong T; Laoitthi P; Sithidetphaiboon P; Thanasanvimon S; Sriuranpong V
Support Care Cancer; 2018 Jul; 26(7):2471-2477. PubMed ID: 29435713
[TBL] [Abstract][Full Text] [Related]
5. Impact of institutional interventions on the rate of paclitaxel hypersensitivity reactions.
Jao ME; Indorf AL; Segal EM; Miske A; Eaton KD; Marsolini T; Ghuman S
J Oncol Pharm Pract; 2024 Jan; 30(1):105-111. PubMed ID: 37021579
[TBL] [Abstract][Full Text] [Related]
6. The added value of H
Cox JM; van Doorn L; Malmberg R; Oomen-de Hoop E; Bosch TM; van den Bemt PMLA; Boere IA; Jager A; Mathijssen RHJ; van Leeuwen RWF
Br J Cancer; 2021 May; 124(10):1647-1652. PubMed ID: 33762718
[TBL] [Abstract][Full Text] [Related]
7. Is ranitidine necessary as premedication for regimens containing paclitaxel? A non-inferiority study.
Montero Pérez O; Martinez Benavides J; González Fernandez T; Guerra Prio S; Romero Domínguez R; Mesía Nin R; Clopés Estela A
Expert Rev Clin Pharmacol; 2023; 16(9):877-883. PubMed ID: 37477611
[TBL] [Abstract][Full Text] [Related]
8. Does long-term medication with a proton pump inhibitor induce a tolerance to H2 receptor antagonist?
Hashimoto H; Kushikata T; Kudo M; Hirota K
J Gastroenterol; 2007 Apr; 42(4):275-8. PubMed ID: 17464455
[TBL] [Abstract][Full Text] [Related]
9. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
Berger MJ; Vargo C; Vincent M; Shaver K; Phillips G; Layman R; Macrae E; Mrozek E; Ramaswamy B; Wesolowski R; Shapiro CL; Lustberg MB
Support Care Cancer; 2015 Jul; 23(7):2019-24. PubMed ID: 25519756
[TBL] [Abstract][Full Text] [Related]
10. Impact of histamine-2 antagonist shortage on the incidence of hypersensitivity reactions to paclitaxel: a reconsideration of premedication protocols in France (PACLIREACT Study).
Strobbe G; Gaboriau L; Abelé M; Villain A; Aelbrecht-Meurisse C; Carnot A; Le Deley MC; Léguillette C; Feutry F; Sakji I; Marliot G
Eur J Clin Pharmacol; 2023 Sep; 79(9):1229-1238. PubMed ID: 37438439
[TBL] [Abstract][Full Text] [Related]
11. Premedication strategy for weekly paclitaxel.
Quock J; Dea G; Tanaka M; Gandara D; Lara P; Lau D
Cancer Invest; 2002; 20(5-6):666-72. PubMed ID: 12197222
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
Berger MJ; Dunlea LJ; Rettig AE; Lustberg MB; Phillips GS; Shapiro CL
Support Care Cancer; 2012 Sep; 20(9):1991-7. PubMed ID: 22089428
[TBL] [Abstract][Full Text] [Related]
13. Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions.
Durham CG; Thotakura D; Sager L; Foster J; Herrington JD
J Oncol Pharm Pract; 2019 Sep; 25(6):1396-1401. PubMed ID: 30419768
[TBL] [Abstract][Full Text] [Related]
14. Dosage effects of histamine-2 receptor antagonist on the primary prophylaxis of non-steroidal anti-inflammatory drug (NSAID)-associated peptic ulcers: a retrospective cohort study.
He Y; Chan EW; Man KK; Lau WC; Leung WK; Ho LM; Wong IC
Drug Saf; 2014 Sep; 37(9):711-21. PubMed ID: 25096957
[TBL] [Abstract][Full Text] [Related]
15. H1 + H2-receptor antagonists for premedication in anaesthesia and surgery: a critical view based on randomized clinical trials with Haemaccel and various antiallergic drugs.
Lorenz W; Doenicke A; Schöning B; Mamorski J; Weber D; Hinterlang E; Schwarz B; Neugebauer E
Agents Actions; 1980 Apr; 10(1 Pt 2):114-24. PubMed ID: 6155762
[TBL] [Abstract][Full Text] [Related]
16. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.
Kloover JS; den Bakker MA; Gelderblom H; van Meerbeeck JP
Br J Cancer; 2004 Jan; 90(2):304-5. PubMed ID: 14974481
[TBL] [Abstract][Full Text] [Related]
17. A multicenter cohort analysis of fractures in histamine-2-receptor antagonist treated pediatric patients.
Fleishman NR; Richardson T; Attard TM
Curr Med Res Opin; 2022 Apr; 38(4):565-570. PubMed ID: 35112645
[TBL] [Abstract][Full Text] [Related]
18. Preventive effect of dexamethasone premedication on the development of infusion-related reaction in breast cancer patients receiving trastuzumab.
Goto E; Hata T; Nishihara M; Neo M; Iwamoto M; Kimura K; Goto M; Rikitake Y
Br J Clin Pharmacol; 2023 Jul; 89(7):2102-2112. PubMed ID: 36709967
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of children and adolescents first prescribed proton pump inhibitors or histamine-2-receptor antagonists: an observational cohort study.
Ruigómez A; Kool-Houweling LMA; García Rodríguez LA; Penning-van Beest FJA; Herings RMC
Curr Med Res Opin; 2017 Dec; 33(12):2251-2259. PubMed ID: 28562108
[TBL] [Abstract][Full Text] [Related]
20. Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer.
Barroso-Sousa R; Vaz-Luis I; Di Meglio A; Hu J; Li T; Rees R; Sinclair N; Milisits L; Leone JP; Constantine M; Faggen M; Briccetti F; Block C; Partridge A; Burstein H; Waks AG; Tayob N; Trippa L; Tolaney SM; Hassett MJ; Winer EP; Lin NU
Oncologist; 2021 Nov; 26(11):927-933. PubMed ID: 34472667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
